Upsher-Smith Laboratories, LLC, a United States-based pharmaceutical company, announced on Monday that it has launched its Pitavastatin Tablets in 1mg, 2mg, and 4mg strengths.
The product is an AB-rated, generic equivalent to the brand product, LIVALO (pitavastatin) tablets.
Sawai USA, Inc, a company of Sawai Group Holdings Co., Ltd. (Sawai), has the ANDA for Pitavastatin tablets and it represents Sawai's first Paragraph IV product to be introduced in the United States. The company is distributing the product in the United States.
ANI Pharmaceuticals launches generic Motegrity tablets
Hikma Pharmaceuticals USA receives FDA approval for diabetes drug
Full Circles Therapeutics advances non-viral gene editing innovation
Induction Healthcare secures national video solution contract in Ireland
Safecor Health acquires Viatris' US unit-dose packaging business
LOG Pharma Primary Packaging opens new clean room
American Regent launches 30 mL Epinephrine Injection, USP in US
EpiVax and CUBRC receive USD2m contract from US FDA
Gilead expands global access to lenacapavir for HIV prevention